A BLUEPRINT TO ADVANCE COLORECTAL CANCER

(CRC) IMMUNOTHERAPIESPresented By:Al B. Benson III, MD FACP FASCOProfessor of MedicineAssociate Director for Cooperative Groups Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Our IntentThis joint effort is supported by a legacy gift honoring Gordon Cole, a stage IV colorectal cancer survivor and Fight Colorectal Cancer board member who passed away in Sept. 2014.

Gordon believed research into the field of immunology will lead to new treatments and improved care for patients. This was based on his own experience after participating in an immunotherapy trial at Duke, which he felt allowed him a longer, richer life.

Support from the Cole family, in his honor has allowed Fight CRC and the Cancer Research Institute to launch a dedicated effort to advance the science and clinical practice of immunotherapy in CRC. Gordon Cole,

former Fight CRC board member

Our PartnershipFight Colorectal Cancer (Fight CRC) is a leading patient advocacy organization based in Washington D.C. committed to research and finding a cure a for colorectal cancer by uniting a community of CRC survivors, scientists, and advocates.

Cancer Research Institute (CRI) established in 1953, is the world’s only nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and cure cancer.

Shared Vision: Advance the Science and Therapeutic Approaches in Immunotherapy for Colorectal Cancer

Our Aims• Convene multi-disciplinary experts in the fields related to colorectal

cancer and immunotherapy• Synthesize the current research• Developing a blueprint to outline next steps and potential for

advancement• Follow the trajectory of the science with advisement of ‘Colorectal

Immunotherapy Workgroup’

Convening of ExpertsCo-Chairs • Al B. Benson III, M.D., FACP, from the Robert H. Lurie

Comprehensive Cancer Center of Northwestern University• Dung T. Le, M.D., from Johns Hopkins Sidney Kimmel

Comprehensive Cancer Center

Gatherings:• December 2, 2015 in New York City to outline current research

and identify next steps and gaps for future research. Over 20 academia and industry partners were represented globally with expertise in oncology, immunology, the microbiome, bench science and translational research.

• Presentation at AACR in April and ongoing meetings at ASCO and calls in the Spring/Summer of 2016.

• GI ASCO Meeting for Final Paper Strategy in January of 2017 Dung Le, Al Benson (co-chairs), Jill O’Donnell-Tormey (CRI), Anjee Davis (Fight CRC)

December 2nd Meeting

Workgroup Members Not Present or Not In Photo: Member OrganizationDr. Michael Morse Duke UniversityDr. Elizabeth Jaffe John HopkinsDr. Christopher Lieu University of ColoradoDr. Stan Hamilton MD AndersonDr. Richard Goldberg Ohio StateDr. Robert Binder University of PittsburghDr. Tom Marsilje Fight CRC Patient AdvocateKeavy McAbee Fight CRC

Member OrganizationDr. Al Benson Northwestern UniversityDr. Emily Chan Vanderbilt UniversityDr. Dustin Deming University of WisconsinDr. Luis Diaz Johns HopkinsDr. Wolf Fridman INSERMDr. Franck Housseau Johns HopkinsDr. S. Peter Kang MerckDr. Smitha Krishnamurth Case Western UniversityDr. Dung T Le Johns HopkinsDr. Wells Messersmith University of ColoradoDr. Cynthia L. Sears Johns HopkinsDr. Neil Segal Memorial Sloan KetteringDr. Arvin Yang Bristol Myers SquibbDr. Rebecca Moss Bristol Myers SquibbDr. Edward Cha GenentechDr. Tom Dubensky Aduro BiotechDr. Aimee Murphy Aduro BiotechAndrea (Andi) Dwyer University of Colorado Fight CRCAnjee Davis Fight CRC PresidentDr. Jill O'Donnell-Tormey CRI PresidentDr. Vanessa Lucy CRI Dr. Arthur Brodsky CRINancy Roach Fight CRC Founder

The Blueprint

Summary of the main biological and clinical findings.

E. Missiaglia et al. Ann Oncol 2014;25:1995-2001

© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Progression in our understanding of CRC subtypes

Presented By David Cunningham

Questions To Be Answered

Summary• In summary, recent data shows the promise of immunotherapy for

CRC in at least a subset of patients. Further studies that include analysis of the immune contexture and the genomic profile of these patients will aid in our understanding of why some CRC patients respond to immunotherapy, while others do not.

• The goal of convening two non-profits with experts in CRC and immunotherapy was to fill the gaps in our understanding of this difficult-to-treat patient population, and provide a research platform for collaborative research to move immunotherapy into the SOC for CRC patients.

Next StepsContinue Convening WorkgroupPublish Blue PrintUtilize Blue Print to Help Set Direction:Prioritize Research Aims

Infrastructure Critical To Perform ResearchPotential Policies to Enhance Research

Develop Partnerships Around Shared VisionDoD Peer Reviewed Cancer Research Program$50M, 13 areas including CRC and immunologyProgram Announcements on grants.gov in April and July

Fund ResearchFight CRC and CRI Devote Funding to Research Aim-Along with a

Donation from Cindy Stowell a 6 Time Jeopardy Winner, who died December 2016 of Colorectal Cancer.

What You Can Do As Advocates

On the Hill advocate for Research Dollars

Consider participation in Clinical Trials for treatment if appropriate

Share Information about Clinical Trials

Donate to Research

Honoring Our Advocates –Cindy Stowell, Gordon Cole and All

of You

Thank youFor Slide Deck and More Information Visit:

www.FightCRC.orgwww.cancerresearch.org